miR‑18a‑5p promotes melanoma cell proliferation and inhibits apoptosis and autophagy by targeting EPHA7 signaling

Guo,Yunlong; Shi,Wenli; Fang,Ruihua

doi:10.3892/mmr.2020.11717

miR‑18a‑5p promotes melanoma cell proliferation and inhibits apoptosis and autophagy by targeting EPHA7 signaling

Authors:
- Yunlong Guo
- Wenli Shi
- Ruihua Fang
View Affiliations

Affiliations: Department of Dermatology, School of Medicine, Guangzhou First People's Hospital, South China University of Technology, Guangzhou, Guangdong 510180, P.R. China
Published online on: November 23, 2020 https://doi.org/10.3892/mmr.2020.11717
Article Number: 79
Copyright: © Guo et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Micro (mi)RNAs serve crucial roles in cancer development although little is known about their cellular mechanisms in the pathogenesis of melanoma. The present study explored the regulatory roles of miR‑18a‑5p in melanoma cell proliferation, apoptosis and autophagy, in addition to its target gene in melanoma cells. miRNA and ephrin receptor A7 (EPHA7) mRNA were analyzed by reverse transcription‑quantitative PCR. Cell Counting Kit‑8 and colony formation assays were performed to examine the cell proliferation rate. Hoechst staining and flow cytometry were performed to investigate cell apoptosis. Western blotting was used to estimate the abundance of proteins. Dual-luciferase reporter assay verified the binding of miRNA with target gene sequences. Melanoma tissues and cell lines exhibited markedly elevated miR‑18a‑5p expression. miR‑18a‑5p inhibitor inhibited proliferation rates, and triggered apoptosis and autophagy marker protein expression in WM266‑4 and A375 cells. It also negatively regulated EPHA7 expression in WM266‑4 and A375 cells by directly binding at the 3'‑untranslated region of EPHA7. miR‑18a‑5p mimics reversed the EPHA7 overexpression‑induced suppression of proliferation, and the EPHA7 overexpression‑induced promotion of apoptosis and autophagy. miR‑18a‑5p triggered proliferation of melanoma cells and inhibited apoptosis and autophagy by directly targeting and inhibiting EPHA7 expression. Thus, the present study aided our understanding of miRNA‑mediated melanoma pathogenesis.

View Figures

View References

1	Bastian BC: The molecular pathology of melanoma: An integrated taxonomy of melanocytic neoplasia. Annu Rev Pathol. 9:239–271. 2014. View Article : Google Scholar : PubMed/NCBI
2	Wahid M, Jawed A, Mandal RK, Dar SA, Akhter N, Somvanshi P, Khan F, Lohani M, Areeshi MY and Haque S: Recent developments and obstacles in the treatment of melanoma with BRAF and MEK inhibitors. Crit Rev Oncol Hematol. 125:84–88. 2018. View Article : Google Scholar : PubMed/NCBI
3	Ankeny JS, Labadie B, Luke J, Hsueh E, Messina J and Zager JS: Review of diagnostic, prognostic, and predictive biomarkers in melanoma. Clin Exp Metastasis. 35:487–493. 2018. View Article : Google Scholar : PubMed/NCBI
4	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
5	Corrie PG, Marshall A, Dunn JA, Middleton MR, Nathan PD, Gore M, Davidson N, Nicholson S, Kelly CG, Marples M, et al: Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): Preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study. Lancet Oncol. 15:620–630. 2014. View Article : Google Scholar : PubMed/NCBI
6	Ichihashi N and Kitajima Y: Chemotherapy induces or increases expression of multidrug resistance-associated protein in malignant melanoma cells. Br J Dermatol. 144:745–750. 2001. View Article : Google Scholar : PubMed/NCBI
7	Li S, Wu Z, Ma P, Xu Y, Chen Y, Wang H, He P, Kang Z, Yin L, Zhao Y, et al: Ligand-dependent EphA7 signaling inhibits prostate tumor growth and progression. Cell Death Dis. 8:e31222017. View Article : Google Scholar : PubMed/NCBI
8	Holland SJ, Gale NW, Gish GD, Roth RA, Songyang Z, Cantley LC, Henkemeyer M, Yancopoulos GD and Pawson T: Juxtamembrane tyrosine residues couple the Eph family receptor EphB2/Nuk to specific SH2 domain proteins in neuronal cells. EMBO J. 16:3877–3888. 1997. View Article : Google Scholar : PubMed/NCBI
9	Wang J, Kataoka H, Suzuki M, Sato N, Nakamura R, Tao H, Maruyama K, Isogaki J, Kanaoka S, Ihara M, et al: Downregulation of EphA7 by hypermethylation in colorectal cancer. Oncogene. 24:5637–5647. 2005. View Article : Google Scholar : PubMed/NCBI
10	Wang LF, Fokas E, Juricko J, You A, Rose F, Pagenstecher A, Engenhart-Cabillic R and An HX: Increased expression of EphA7 correlates with adverse outcome in primary and recurrent glioblastoma multiforme patients. BMC Cancer. 8:792008. View Article : Google Scholar : PubMed/NCBI
11	Xia J, Jia P, Hutchinson KE, Dahlman KB, Johnson D, Sosman J, Pao W and Zhao Z: A meta-analysis of somatic mutations from next generation sequencing of 241 melanomas: A road map for the study of genes with potential clinical relevance. Mol Cancer Ther. 13:1918–198. 2014. View Article : Google Scholar : PubMed/NCBI
12	Lin S and Gregory RI: MicroRNA biogenesis pathways in cancer. Nat Rev Cancer. 15:321–333. 2015. View Article : Google Scholar : PubMed/NCBI
13	Li Y, Qiu C, Tu J, Geng B, Yang J, Jiang T and Cui Q: HMDD v2.0: A database for experimentally supported human microRNA and disease associations. Nucleic Acids Res. 42((Database Issue)): D1070–D1074. 2014. View Article : Google Scholar : PubMed/NCBI
14	Valastyan S, Reinhardt F, Benaich N, Calogrias D, Szász AM, Wang ZC, Brock JE, Richardson AL and Weinberg RA: Retraction notice to: A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. Cell. 161:4172015. View Article : Google Scholar : PubMed/NCBI
15	Liu M, Zhou K and Cao Y: MicroRNA-944 affects cell growth by targeting EPHA7 in non-small cell lung cancer. Int J Mol Sci. 17:14932016. View Article : Google Scholar
16	Penna E, Orso F, Cimino D, Tenaglia E, Lembo A, Quaglino E, Poliseno L, Haimovic A, Osella-Abate S, De Pittà C, et al: microRNA-214 contributes to melanoma tumour progression through suppression of TFAP2C. EMBO J. 30:1990–2007. 2011. View Article : Google Scholar : PubMed/NCBI
17	Stark MS, Klein K, Weide B, Haydu LE, Pflugfelder A, Tang YH, Palmer JM, Whiteman DC, Scolyer RA, Mann GJ, et al: The prognostic and predictive value of melanoma-related MicroRNAs using tissue and serum: A MicroRNA expression analysis. EBioMedicine. 2:671–680. 2015. View Article : Google Scholar : PubMed/NCBI
18	Chen X, Wu L, Li D, Xu Y, Zhang L, Niu K, Kong R, Gu J, Xu Z, Chen Z and Sun J: Radiosensitizing effects of miR-18a-5p on lung cancer stem-like cells via downregulating both ATM and HIF-1α. Cancer Med. 7:3834–3847. 2018. View Article : Google Scholar : PubMed/NCBI
19	Liang C, Zhang X, Wang HM, Liu XM, Zhang XJ, Zheng B, Qian GR and Ma ZL: MicroRNA-18a-5p functions as an oncogene by directly targeting IRF2 in lung cancer. Cell Death Dis. 8:e27642017. View Article : Google Scholar : PubMed/NCBI
20	Linck L, Liebig J, Völler D, Eichner N, Lehmann G, Meister G and Bosserhoff A: MicroRNA-sequencing data analyzing melanoma development and progression. Exp Mol Pathol. 105:371–379. 2018. View Article : Google Scholar : PubMed/NCBI
21	World Medical Association: World medical association declaration of Helsinki: Ethical principles for medical research involving human subjects. JAMA. 310:2191–2194. 2013. View Article : Google Scholar : PubMed/NCBI
22	Livak JK and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
23	Dawson MA and Kouzarides T: Cancer epigenetics: From mechanism to therapy. Cell. 150:12–27. 2012. View Article : Google Scholar : PubMed/NCBI
24	Kita Y, Yonemori K, Osako Y, Baba K, Mori S, Maemura K and Natsugoe S: Noncoding RNA and colorectal cancer: Its epigenetic role. J Hum Genet. 62:41–47. 2017. View Article : Google Scholar : PubMed/NCBI
25	Calvano Filho CM, Calvano-Mendes DC, Carvalho KC, Maciel GA, Ricci MD, Torres AP, Filassi JR and Baracat EC: Triple-negative and luminal A breast tumors: Differential expression of miR-18a-5p, miR-17-5p, and miR-20a-5p. Tumour Biol. 35:7733–7741. 2014. View Article : Google Scholar : PubMed/NCBI
26	Zhang N, Zhang H, Liu Y, Su P, Zhang J, Wang X, Sun M, Chen B, Zhao W, Wang L, et al: SREBP1, targeted by miR-18a-5p, modulates epithelial-mesenchymal transition in breast cancer via forming a co-repressor complex with Snail and HDAC1/2. Cell Death Differ. 26:843–859. 2019. View Article : Google Scholar : PubMed/NCBI
27	Zhang G, Han G, Zhang X, Yu Q, Li Z, Li Z and Li J: Long non-coding RNA FENDRR reduces prostate cancer malignancy by competitively binding miR-18a-5p with RUNX1. Biomarkers. 23:435–445. 2018. View Article : Google Scholar : PubMed/NCBI
28	Burgess JT, Bolderson E, Adams MN, Baird AM, Zhang SD, Gately KA, Umezawa K, O'Byrne KJ and Richard DJ: Activation and cleavage of SASH1 by caspase-3 mediates an apoptotic response. Cell Death Dis. 7:e24692016. View Article : Google Scholar : PubMed/NCBI
29	Guan M, Xu C, Zhang F and Ye C: Aberrant methylation of EphA7 in human prostate cancer and its relation to clinicopathologic features. Int J Cancer. 124:88–94. 2009. View Article : Google Scholar : PubMed/NCBI
30	Oricchio E and Wendel HG: Mining the cancer genome uncovers therapeutic activity of EphA7 against lymphoma. Cell Cycle. 11:1076–1080. 2012. View Article : Google Scholar : PubMed/NCBI
31	Wang J, Li G, Ma H, Bao Y, Wang X, Zhou H, Sheng Z, Sugimura H, Jin J and Zhou X: Differential expression of EphA7 receptor tyrosine kinase in gastric carcinoma. Hum Pathol. 38:1649–1656. 2007. View Article : Google Scholar : PubMed/NCBI
32	Li MY, Zhu XL, Zhao BX, Shi L, Wang W, Hu W, Qin SL, Chen BH, Zhou PH, Qiu B, et al: Adrenomedullin alleviates the pyroptosis of leydig cells by promoting autophagy via the ROS-AMPK-mTOR axis. Cell Death Dis. 10:4892019. View Article : Google Scholar : PubMed/NCBI
33	Komatsu M and Ichimura Y: Physiological significance of selective degradation of p62 by autophagy. FEBS Lett. 584:1374–1378. 2010. View Article : Google Scholar : PubMed/NCBI
34	Mathew R, Karp CM, Beaudoin B, Vuong N, Chen G, Chen HY, Bray K, Reddy A, Bhanot G, Gelinas C, et al: Autophagy suppresses tumorigenesis through elimination of p62. Cell. 137:1062–1075. 2009. View Article : Google Scholar : PubMed/NCBI
35	Li Z, Jiang K, Zhu X, Lin G, Song F, Zhao Y, Piao Y, Liu J, Cheng W, Bi X, et al: Encorafenib (LGX818), a potent BRAF inhibitor, induces senescence accompanied by autophagy in BRAFV600E melanoma cells. Cancer Lett. 370:332–344. 2016. View Article : Google Scholar : PubMed/NCBI
36	Meng XX, Yao M, Zhang XD, Xu HX and Dong Q: ER stress-induced autophagy in melanoma. Clin Exp Pharmacol Physiol. 42:811–816. 2015. View Article : Google Scholar : PubMed/NCBI